Xeris Biopharma Holdings
XERS
35 hedge funds and large institutions have $184M invested in Xeris Biopharma Holdings in 2018 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 17 increasing their positions, 9 reducing their positions, and 3 closing their positions.
89% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 9
1.13% more ownership
Funds ownership: 50.6% → 51.72% (+1.1%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1% less capital invested
Capital invested by funds: $185M → $184M (-$1.76M)
3% less funds holding
Funds holding: 36 → 35 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$8.99M |
| 2 |
BlackRock
New York
|
+$5.03M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.47M |
| 4 |
State Street
Boston,
Massachusetts
|
+$718K |
| 5 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$432K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$5.7M |
| 2 |
PA
Perceptive Advisors
New York
|
-$3.53M |
| 3 |
LCM
Landscape Capital Management
Englewood,
New Jersey
|
-$1.08M |
| 4 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$976K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$167K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Wells Fargo
San Francisco,
California
| $56K | +$47.4K | +2,362 | +253% |
|
27
JP Morgan Chase
New York
| $29K | +$3.55K | +177 | +12% |
|
28
Citigroup
New York
| $25K | -$7.74K | -386 | -21% |
|
|
TRCT
29
Tower Research Capital (TRC)
New York
| $17K | -$61.6K | -3,072 | -75% |
|
30
Legal & General Group
London,
United Kingdom
| $17K | – | – | – |
|
31
Barclays
London,
United Kingdom
| $15K | -$32.8K | -1,636 | -66% |
|
|
AIP
32
Ameritas Investment Partners
Lincoln,
Nebraska
| $9K | – | – | – |
|
|
SO
33
STRS Ohio
Columbus,
Ohio
| $5K | -$32.1K | -1,600 | -84% |
|
34
Daiwa Securities Group
Tokyo,
Japan
| $5K | +$6.02K | +300 | New |
|
35
Bank of Montreal
Toronto,
Ontario, Canada
| $2K | +$963 | +48 | +104% |
|
|
PA
36
Perceptive Advisors
New York
| – | -$3.53M | -200,627 | Closed |
|
|
LCM
37
Landscape Capital Management
Englewood,
New Jersey
| – | -$1.08M | -57,045 | Closed |
|
|
IA
38
IFP Advisors
Tampa,
Florida
| – | -$4K | -200 | Closed |
|
XERS Hedge Fund Activity: Q4 2018 in Review
35 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Xeris Biopharma Holdings (XERS) for Q4 2018, worth a combined $184M — down 0.95% from $185M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of XERS and 2 opened new positions — a net loss of 1 holder — while 9 trimmed existing stakes and 17 added.
The largest buyer was Fidelity Investments, adding an estimated $8.99M. The largest seller was Sabby Management, cutting an estimated $5.7M.
- 35 institutional investors held Xeris Biopharma Holdings (XERS) as of Q4 2018, down from 36 in Q3 2018.
- Funds reported $184M of Xeris Biopharma Holdings stock for Q4 2018, down 0.95% quarter-over-quarter.
- 2 funds opened new Xeris Biopharma Holdings positions in Q4 2018 and 3 closed out, a net change of -1 holder.
- The largest Xeris Biopharma Holdings buyer in Q4 2018 was Fidelity Investments, an estimated $8.99M added.
- The largest Xeris Biopharma Holdings seller in Q4 2018 was Sabby Management, an estimated $5.7M sold.
Based on aggregated 13F filings for Q4 2018.